CARLOS
TAXONERA SAMSO
Profesor asociado de Ciencias de la Salud
![Foto de CARLOS](/img/nophoto.png)
![Foto de Instituto de Investigación Sanitaria Gregorio Marañón](/img/noimage_org.png)
Instituto de Investigación Sanitaria Gregorio Marañón
Madrid, EspañaPublicaciones en colaboración con investigadores/as de Instituto de Investigación Sanitaria Gregorio Marañón (9)
2022
-
Cost-effectiveness analysis of using innovative therapies for the management of moderate-to-severe ulcerative colitis in Spain
Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 22, Núm. 1, pp. 73-83
2018
-
Serial tuberculin skin tests improve the detection of latent tuberculosis infection in patients with inflammatory bowel disease
Journal of Crohn's and Colitis, Vol. 12, Núm. 11, pp. 1270-1279
2017
-
Adalimumab vs azathioprine in the prevention of postoperative Crohn's disease recurrence. A GETECCU randomised trial
Journal of Crohn's and Colitis, Vol. 11, Núm. 11, pp. 1293-1301
-
Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
Inflammatory Bowel Diseases, Vol. 23, Núm. 8, pp. 1394-1402
-
Early tuberculin skin test for the diagnosis of latent tuberculosis infection in patients with inflammatory Bowel disease
Journal of Crohn's and Colitis, Vol. 11, Núm. 7, pp. 792-800
-
Evolution after Anti-TNF Discontinuation in Patients with Inflammatory Bowel Disease: A Multicenter Long-Term Follow-Up Study
American Journal of Gastroenterology, Vol. 112, Núm. 1, pp. 120-131
2016
-
Diagnostic performance of the simple clinical colitis activity index self-administered online at home by patients with ulcerative colitis: CRONICA-UC study
American Journal of Gastroenterology, Vol. 111, Núm. 2, pp. 261-268
-
Standardization of the homogeneous mobility shift assay protocol for evaluation of anti-infliximab antibodies. Application of the method to Crohn's disease patients treated with infliximab
Biochemical Pharmacology, Vol. 122, pp. 33-41
-
Ustekinumab for the Treatment of Refractory Crohn's Disease: The Spanish Experience in a Large Multicentre Open-label Cohort
Inflammatory Bowel Diseases, Vol. 22, Núm. 7, pp. 1662-1669